Rankings
▼
Calendar
▼
DNTH Q2 2017 Earnings Report — Dianthus Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
Dianthus Therapeutics, Inc.
DNTH
Q2 2017 Earnings
Reported June 29, 2017
Quarter Comparison
Revenue
Operating Income
EPS (Diluted)
Free Cash Flow
Metric
Q2 2017
Q1 2017
Q2 2016
QoQ Change
YoY Change
Revenue
$0
$0
—
—
—
Op. Income
-$16M
-$5M
—
-227.0%
—
EPS (Diluted)
$-7.12
$-2.18
—
-226.6%
—
Free Cash Flow
-$5M
-$5M
—
-19.4%
—
marketcaparena.com
Income Statement
Item
Amount
REVENUE
$0
Cost of Revenue
$0
GROSS PROFIT
$0
R&D Expenses
$14M
Selling & Marketing
$0
General & Administrative
$2M
SG&A Expenses
$2M
Other Expenses
$0
Operating Expenses
$16M
Cost & Expenses
$16M
OPERATING INCOME
-$16M
Interest Income
$0
Interest Expense
$0
Other Income/Expenses
$0
INCOME BEFORE TAX
-$16M
Income Tax Expense
$0
Net Income from Continuing Ops
-$16M
Net Income from Discontinued Ops
$0
Other Adjustments
$0
NET INCOME
-$16M
Net Income Deductions
-$344.0K
BOTTOM LINE NET INCOME
-$15M
D&A
$96.0K
EBIT
-$16M
EBITDA
-$16M
EPS
-$7
EPS Diluted
-$7
marketcaparena.com
Cash Flow Statement
Item
Amount
Net Income
-$16M
Depreciation & Amortization
$96.0K
Stock-Based Compensation
$607.0K
Deferred Income Tax
$0
Other Non-Cash Items
$9M
Change in Working Capital
$1M
OPERATING CASH FLOW
-$5M
Capital Expenditure
-$931.0K
Acquisitions (Net)
$0
Purchases of Investments
$0
Sales/Maturities of Investments
$0
Other Investing Activities
$30.0K
NET CASH FROM INVESTING
-$901.0K
Net Debt Issuance
$0
Common Stock Repurchased
-$171.0K
Common Dividends Paid
$0
Other Financing Activities
$0
NET CASH FROM FINANCING
$63M
FREE CASH FLOW
-$5M
Net Change in Cash
$58M
marketcaparena.com
← FY 2017
DNTH Overview
Q3 2017 →